학술논문
Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.
Document Type
Academic Journal
Author
DuRoss AN; Department of Pharmaceutical Sciences, Oregon State University, Portland, Oregon, USA.; Phan J; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Lazar AJ; Department of Pathology and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Walker JM; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Guimaraes AR; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon, USA.; Baas C; National Cancer Institute, Bethesda, Maryland, USA.; Krishnan S; Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, Florida, USA.; Thomas CR Jr; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Radiation Oncology, Norris Cotton Cancer Center, Dartmouth University, Lebanon, New Hampshire, USA.; Sun C; Department of Pharmaceutical Sciences, Oregon State University, Portland, Oregon, USA.; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Bagley AF; Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Radiation Oncology, Samaritan Health Services, Corvallis, Oregon, USA.
Source
Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101508311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1939-0041 (Electronic) Linking ISSN: 19390041 NLM ISO Abbreviation: Wiley Interdiscip Rev Nanomed Nanobiotechnol Subsets: MEDLINE
Subject
Language
English
Abstract
Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
(© 2022 Wiley Periodicals LLC.)
(© 2022 Wiley Periodicals LLC.)